EIDD-2801 是核糖核苷類似物 EIDD-1931 的口服生物可利用的異丙酯前藥。EIDD-2801 顯示出廣泛的抗流感病毒 (influenza virus) 和冠狀病毒 (coronaviruses) 的活性，如 SARS-CoV-2，MERS-CoV，SARS-CoV。EIDD-2801 有用于 COVID-19 和季節(jié)性，流行性流感的潛力。 

EIDD-2801可抑制多種RNA病毒的復(fù)制，包括SARS-CoV-2（COVID-19的致病因子），通過(guò)兩種不同冠狀病毒（SARS-CoV1和MERS）的動(dòng)物研究，證明EIDD-2801可以改善肺功能、減少體重減輕并減少肺中的病毒量。除了針對(duì)冠狀病毒的活性外，在實(shí)驗(yàn)室研究中，EIDD-2801還顯示出針對(duì)季節(jié)性流感、呼吸道合胞病毒、基孔肯雅病毒、埃博拉病毒、委內(nèi)瑞拉馬腦炎病毒和東部馬腦炎病毒的活性。

Molnupiravir ;EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. EIDD-2801 is a prodrug of EIDD-1931.